2011-001462-17: Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies. |
|
|
| Ongoing | 2/3 | 5236 | Europe | Epirubicin, Cyclophosphamide, Paclitaxel, Tamoxifen, Anastrozole, Letrozole, Exemestan, trastuzumab emtansine (T-DM1), Trastuzumab, Paclitaxel-Albumin, Gemcitabine, Carboplatin, Pertuzumab, Myocet, RO530-4020/xxx, RO4368451, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Powder for solution for infusion, Kadcyla, Herceptin 150 mg, Abraxane, Perjeta | Westdeutsche Studiengruppe GmbH, Genomic Health , Inc., Roche Pharma AG, Celgene Corp., Amgen, TEVA GmbH, Bayer AG | Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status., Early diagnosed breast cancer at first occurence, with hormone receptor over-expressing tumor and any lymph node involvement (from none to any)., Diseases [C] - Cancer [C04] | | | | |
SMA-BC-002, NCT05978648: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy |
|
|
| Recruiting | 2 | 116 | RoW | Trilaciclib, COSELA®, G1T28, Epirubicin, Cyclophosphamide, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab | wang shusen | Breast Neoplasms | 12/26 | 12/27 | | |
NCT03304080: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast |
|
|
| Active, not recruiting | 1/2 | 44 | US | Anastrozole, Arimidex, Palbociclib, Ibrance, Trastuzumab, Herceptin, Pertuzumab, Perjeta | Icahn School of Medicine at Mount Sinai, Herbert Irving Comprehensive Cancer Center, Weill Medical College of Cornell University, NYU Langone Health | Breast Neoplasms, Breast Diseases | 07/24 | 12/24 | | |
